本报讯(记者丁蓉)8月22日晚间，广州金域医学（603882）检验集团股份有限公司(以下简称"金域医学") 发布2025年半年度报告。公司上半年实现营业收入29.97亿元，因信用减值损失2.72亿元；归属于上市公 司股东的净利润为亏损0.85亿元。公司经营性现金流表现向好，上半年达3.50亿元，同比增长9.2倍。 今年上半年，金域医学通过产品组合优化、持续创新、打造区域检验中心方案，构建起差异化竞争优 势；通过精益运营、数智赋能，构建成本竞争优势，为公司长期稳定发展进一步夯实基础。 在构建以数据要素驱动的第二增长曲线方面，公司取得亮眼成绩，作为唯一医疗机构成功入选国家可信 数据空间创新发展试点。 三级医院收入占比持续提升 金域医学在肿瘤、感染、血液、神经等疾病领域推出多项高性价比惠民产品体系。今年上半年，公司三 级医院收入占比持续提升，达51.18%，同比提升5.43个百分点。 公司继续以产学研合作的模式赋能临床，累计与超210家医院、高校、科研院所等达成合作。上半年， 金域医学携手北京大学人民医院、北京地坛医院、武汉协和医院、复旦大学附属儿科医院等三甲医院开 展多中心科研、联合实验室建设等合作；联合中国医学 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-037 广州金域医学检验集团股份有限公司 关于召开2025年第二次临时股东会的通知 一、召开会议的基本情况 (一)股东会类型和届次 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 9 日 14 点 30 分 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 股东会召开日期：2025年9月9日 ? 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 召开地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 9 月 9 日 至2025 年 9 月 9 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30 ...

－自有资金 | 公司代码：603882 | 广州金域医学检验集团股份有限公司2025 年半年度报告摘要 公司简称：金域医学 | | --- | --- | | | 广州金域医学检验集团股份有限公司 | | | 广州金域医学检验集团股份有限公司2025 年半年度报告摘要 第一节 重要提示 | | 展规划，投资者应当到 | www.sse.com.cn 网站仔细阅读半年度报告全文。 | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | 无 | | | | 第二节 公司基本情况 | | | 公司股票简况 | | 股票种类 | 股票上市交易所 股票简称 股票代码 变更前股票 | | 简称 | | | 联系人和联系方式 | 董事会秘书 证券事务代表 | | 姓名 | 汪令来 肖东琪 | | 办公地址 | 广州市国际生物岛螺旋三路10 广州市国际生物岛螺旋三路 | | 10 | | | 号 | 号 | | 电子信箱 | sid@kingmed.com.cn | | | 单位：元 币种：人民币 | | | 本报告期末比上年度末 | | 本报告期末 | 上年度末 | | | 增减(% ...

证券代码：603882 证券简称：金域医学 公告编号：2025-038 广州金域医学检验集团股份有限公司 关于计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、计提资产减值准备情况概述 为了客观、公允地反映广州金域医学检验集团股份有限公司（以下简称"公 司"）2025 年半年度的财务状况以及经营成果，根据《企业会计准则》相关规 定和公司会计政策，公司对截至 2025 年 6 月 30 日的合并报表范围内各项资产进 行了减值测试，相应计提资产减值准备。详见下表： 单位：人民币元 类别 2025 年 1-6 月 一、信用减值损失 272,474,717.40 其中：应收账款减值损失 271,491,843.98 其他应收款信用减值损失 982,873.42 二、资产减值损失 -125,413.97 其中：合同资产减值损失 -125,413.97 合计 272,349,303.43 二、计提资产减值准备的具体说明 （一）信用减值损失 根据《企业会计准则第 22 号——金融工具确认和计量》的规定，公司对以 摊 ...

期内，共建业务收入同比增长30%，四年CAGR达48%，主要受益于多家大型三甲医院项目的成功落 地。展望下半年，公司计划深化与领先医疗机构的战略合作，推动更多标杆性项目落地。 CRO业务收入同比增长18%。公司通过与国内外领先药企的深度合作，持续巩固糖尿病领域优势地位， 在NASH领域取得强劲表现，并在实体瘤治疗领域实现创新突破，拓展全新业务版图。 艾迪康控股(09860)发布截至2025年6月30日止6个月中期业绩，该集团取得收益人民币12.71亿元(单位下 同)，同比减少13.31%;母公司拥有人应占溢利2727.3万元，同比减少73.15%;每股盈利0.04元。 公司的总收入达12.7亿，同比下滑13.3%。尽管经济周期调整及政策变动给公司带来短期压力，但本公 司的业务组合持续巩固其韧性，并支撑了多个板块的良好发展势头。 ...

2025年5月，集团宣布收购了中国血液病诊断领域的标杆企业元德友勤及其IVD附属公司元德维康，与 二者的协同计划正稳步推进。通过三级医院客户详细地图分析，公司已识别出一批具有高合作潜力的目 标客户，并已锁定若干重点医院开展跟进与协同上量。未来，公司将与元德友勤进一步深化协同，充分 发挥在血液线上高度差异化的竞争优势。 格隆汇8月22日丨艾迪康控股(09860.HK)公布中期业绩，截 至2025年6月30日止六个月，集团收益为人 民币12.706亿元，同比减少约13.3%；期内溢利为人民币2860万元，同比减少约72.4%。 尽管经济周期调整及政策变动给公司带来短期压力，但公司的业务组合持续巩固其韧性，并支撑了多个 板块的良好发展势头。 2025年上半年，共建业务收入同比增长30%，四年CAGR达48%，主要受益于多家大型三甲医院项目的 成功落地。展望下半年，公司计划深化与领先医疗机构的战略合作，推动更多标杆性项目落地。CRO 业务收入同比增长18%。公司通过与国内外领先药企的深度合作，持续巩固糖尿病领域优势地位，在 NASH领域录得强劲表现，并在实体瘤治疗领域实现创新突破，拓展全新业务版图。特检业务收入同比 ...

Financial Performance - The company's total revenue for the first half of 2025 was 4.936 billion yuan, a decrease of 20.61% year-on-year [1] - The net profit attributable to shareholders was 10.2772 million yuan, down 85.68% compared to the previous year [1] - The gross profit margin was 27.59%, a slight decrease of 0.36% year-on-year, while the net profit margin fell by 40.02% to 1.67% [1] - Total accounts receivable accounted for 56.82% of the latest annual revenue, indicating a significant receivables issue [1] - The company reported a significant increase in operating cash flow per share, which was 0.44 yuan, up 199.87% year-on-year [1] Cash Flow and Investment Activities - The net cash flow from operating activities increased by 199.56% due to improved cost control and reduced cash outflows [3] - The net cash flow from investing activities rose by 79.82% as long-term asset investments decreased compared to the previous period [3] - The net cash flow from financing activities decreased by 50.88% due to an increase in loan repayments [3] Business Model and Strategy - The company relies heavily on research and marketing to drive its performance, necessitating a thorough examination of these underlying drivers [7] - The company aims to differentiate itself in a highly competitive market through scale and cost advantages, unique technology products, innovative service models, and digital empowerment [10] Market Position and Fund Holdings - The largest fund holding the company's shares is the Changcheng Consumption Value Mixed A fund, with a current scale of 421 million yuan [9] - Analysts expect the company's performance in 2025 to reach 435 million yuan, with an average earnings per share of 0.7 yuan [8]

Core Insights - The visit to the Xi'an Regional Medical Testing Center highlighted advancements in smart medical testing laboratories utilizing "Internet+" technology to enhance efficiency and quality in testing processes [1][3] - The event fostered a consensus among entrepreneurs on the importance of cross-sector collaboration to promote high-quality development in the precision medicine industry [3] Group 1: Medical Testing Center Developments - The Xi'an Medical Testing Center, built under a BOT model, features a core laboratory capable of conducting over 3,000 medical testing projects and aims to upgrade 15 regional center laboratories in collaboration with 15 hospitals [4] - The center's establishment is expected to significantly improve the diagnostic capabilities of local medical institutions while reducing redundant investments in hospital testing departments [4] Group 2: Educational Initiatives and Collaboration - A lecture on the relationship between genetic diseases and genes was conducted, providing entrepreneurs with insights into the mechanisms of genetic diseases [3] - The event included discussions on precision medicine, resource integration, and collaborative development, emphasizing the need for ongoing partnerships in the industry [3]

Group 1 - The core point of the article highlights the stock performance of Kingmed Diagnostics, which closed at 30.73 yuan on August 5, showing a slight decline of 0.09 yuan or 0.29% from the previous trading day [1] - On August 5, the stock opened at 30.85 yuan, reached a high of 31.38 yuan, and a low of 30.40 yuan, with an overall trading range of 3.18% and a trading volume of 84,190 hands, amounting to 260 million yuan [1] - Kingmed Diagnostics is a leading third-party medical testing institution in China, with its main business covering medical testing, pathological diagnosis, and research services, supported by a nationwide service network [1] Group 2 - At 13:01 on August 5, Kingmed Diagnostics experienced a rapid rebound, with a price increase of over 2% within 5 minutes, rising from 30.96 yuan to 31.21 yuan, with a transaction volume of 165 million yuan during that period [1] - Despite a net outflow of 7.02 million yuan in main funds by the end of the trading day, there was a cumulative net inflow of 53.83 million yuan over the past five trading days [1]

Group 1 - The sixth National Excellent Builders of Socialism with Chinese Characteristics award ceremony was held, recognizing 100 individuals, including Liang Yaoming, CEO of KingMed Diagnostics [1] - The award is jointly evaluated by several government departments and honors non-public economic individuals for their patriotism, law-abiding business practices, innovation, and social contributions [1] - Liang Yaoming expressed commitment to advancing the integration of biotechnology and new information technology to enhance diagnostic capabilities and contribute to the "Healthy China" initiative [1] Group 2 - KingMed Diagnostics pioneered the third-party medical testing industry in the 1990s, providing diagnostic services to various medical institutions [2] - The company has established a comprehensive service system that innovates diagnostic technologies and enhances clinical capabilities for rare and complex diseases [2] - KingMed Diagnostics has become a leading third-party medical testing institution in China, covering over 90% of the population and collaborating with more than 23,000 medical institutions nationwide [2]